NADMED Funding news – Helnsinki-based NADMED Secures €3.5 Million in Series A Round Funding

Nordic Science Investments (NSI), a Finnish startup investor with a focus on science, led the round. Further investment came from many private European investors, a grant from Business Finland, and prior investors Voima Ventures and University of Helsinki Funds.

Along with glutathiones, a potent antioxidant in the body, NADs are essential molecules present in every cell of the body. They play a critical role in energy production, cellular repair, and growth. It is crucial to measure NAD and glutathione levels since abnormalities have been connected to a number of age-related illnesses, such as cancer, heart and brain diseases, metabolic disorders, and muscular atrophy.

Read also - Gaussion funding news – London-based Gaussion Raises $12 Million in Series A Round Funding

NAD levels can also drop as a result of other stressors like inadequate nutrition, a post-inflammatory condition, or adverse drug reactions. In addition, prolonged COVID, inexplicable fatigue, muscle weakness, and unexpected pharmacological side effects should all be taken into account when measuring NAD.

Based on years of research conducted in the University of Helsinki laboratory of Professor Anu Suomalainen Wartiovaara, NADMED's testing technology is the first available on the market that measures all four NADs using fresh blood samples in a fast and efficient manner with an accuracy comparable to mass spectrometry.

The methodology relies on a precise colorimetric measurement that may be carried out using even very small volumes of blood. The same sample's glutathione forms are measured in a similar way.

Jari Närhi, CEO and co-founder at NADMED said, “In the coming years, metabolism will be the hottest topic in medicine and biology, especially when applied to personalized health and disease understanding. In this dawning age of metabolism, NAD will be the new DNA, We are pleased and grateful for the funding from these insightful investors to spread and further develop the unique technology to measure all REDOX metabolites – something that was not possible before. This investment will enable us to bring new capabilities to diagnostics, therapy monitoring, personalized medicine, and advancement of metabolic science for the benefit of mankind.”

Lead investor NSI concentrates on assisting the Nordic and Baltic regions' most promising science-based entrepreneurs, especially those with disruptive technologies and creative solutions based on in-depth academic research. Numerous deep tech, health tech, and life sciences startups are included in their portfolio.

Alexandra Gylfe, Founding Partner at NSI said, “Investing in NADMED was a compelling choice for us, driven by the exceptional expertise of Professor Anu Suomalainen Wartiovaara, a globally recognized leader in metabolic disorders. For investors, the company’s diverse target market not only provides robust risk mitigation but also presents exciting growth opportunities across multiple sectors, We are eager to leverage our strong U.S. science and biotech networks to support NADMED’s expansion into the U.S. market, enhancing their global footprint and driving further success in the years to come.”

About NADMED

A startup business called NADMED Oy is launching a novel, high-throughput technique for measuring NADs from whole blood and other sample matrices.